ArticleESMO real world data and digital oncology2026
Real-world survival benefit of adding durvalumab to chemotherapy in cholangiocarcinoma: a retrospective cohort analysis from a German Comprehensive Cancer Centre.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Advanced biliary tract cancers (BTCs) carry a poor prognosis. Gemcitabine/platinum chemotherapy was the first-line standard until TOPAZ-1 and KEYNOTE-966 established immune checkpoint inhibitor-based combinations as a new standard. Real-world data with a chemotherapy-only comparator remain limited. Patients and methods: We retrospectively analyzed 172 patients with advanced BTC treated at the West German Cancer Centre (2018-2024): a durvalumab cohort ( Results: In the matched cohort ( Conclusions: These real-world data support the clinical benefit of adding durvalumab to gemcitabine/platinum chemotherapy in patients with advanced BTC, consistent with TOPAZ-1 and KEYNOTE-966. Given the retrospective design, findings should be regarded as supportive of, rather than exceeding, pivotal trial data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.